These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 18039096

  • 1. Von Hippel-Lindau disease.
    Kaelin WG.
    Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
    [Abstract] [Full Text] [Related]

  • 2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 3. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [Abstract] [Full Text] [Related]

  • 4. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG.
    Cold Spring Harb Symp Quant Biol; 2005 Sep 15; 70():159-66. PubMed ID: 16869749
    [Abstract] [Full Text] [Related]

  • 5. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K, Cartwright E, Freund S, Bycroft M, Buchberger A.
    J Biol Chem; 2009 Apr 17; 284(16):10514-22. PubMed ID: 19228690
    [Abstract] [Full Text] [Related]

  • 6. The von Hippel-Lindau tumor suppressor gene.
    Kondo K, Kaelin WG.
    Exp Cell Res; 2001 Mar 10; 264(1):117-25. PubMed ID: 11237528
    [Abstract] [Full Text] [Related]

  • 7. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
    Okumura F, Uematsu K, Byrne SD, Hirano M, Joo-Okumura A, Nishikimi A, Shuin T, Fukui Y, Nakatsukasa K, Kamura T.
    Mol Cell Biol; 2016 Jun 15; 36(12):1803-17. PubMed ID: 27090638
    [Abstract] [Full Text] [Related]

  • 8. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.
    Calzada MJ.
    Clin Transl Oncol; 2010 Mar 15; 12(3):160-5. PubMed ID: 20231120
    [Abstract] [Full Text] [Related]

  • 9. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL, Gillespie D, House P, Layfield L, Shelton C.
    J Neurosurg; 2004 Mar 15; 100(3):488-97. PubMed ID: 15035285
    [Abstract] [Full Text] [Related]

  • 10. Role of VHL gene mutation in human cancer.
    Kim WY, Kaelin WG.
    J Clin Oncol; 2004 Dec 15; 22(24):4991-5004. PubMed ID: 15611513
    [Abstract] [Full Text] [Related]

  • 11. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
    Iida K, Okimura Y, Takahashi K, Inomata S, Iguchi G, Kaji H, Chihara K.
    Int J Mol Med; 2004 Mar 15; 13(3):401-4. PubMed ID: 14767570
    [Abstract] [Full Text] [Related]

  • 12. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
    Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang GJ, Kondo K, Nosé V, Kaelin WG.
    Am J Pathol; 2006 Feb 15; 168(2):574-84. PubMed ID: 16436671
    [Abstract] [Full Text] [Related]

  • 13. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI, Jewett MA, Ohh M.
    Am J Physiol Renal Physiol; 2004 Jul 15; 287(1):F1-6. PubMed ID: 15180922
    [Abstract] [Full Text] [Related]

  • 14. Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome.
    Gaal J, van Nederveen FH, Erlic Z, Korpershoek E, Oldenburg R, Boedeker CC, Kontny U, Neumann HP, Dinjens WN, de Krijger RR.
    J Clin Endocrinol Metab; 2009 Nov 15; 94(11):4367-71. PubMed ID: 19808854
    [Abstract] [Full Text] [Related]

  • 15. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
    Kaelin WG.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
    [Abstract] [Full Text] [Related]

  • 16. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
    Kapitsinou PP, Haase VH.
    Cell Death Differ; 2008 Apr 15; 15(4):650-9. PubMed ID: 18219317
    [Abstract] [Full Text] [Related]

  • 17. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH.
    Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720
    [Abstract] [Full Text] [Related]

  • 18. The von hippel-lindau tumor suppressor protein: an update.
    Kaelin WG.
    Methods Enzymol; 2007 Nov 16; 435():371-83. PubMed ID: 17998064
    [Abstract] [Full Text] [Related]

  • 19. Von Hippel-Lindau disease and endocrine tumour susceptibility.
    Woodward ER, Maher ER.
    Endocr Relat Cancer; 2006 Jun 16; 13(2):415-25. PubMed ID: 16728571
    [Abstract] [Full Text] [Related]

  • 20. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 Jun 16; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.